2017
Cetuximab Combined With Induction Oxaliplatin and Capecitabine, Followed by Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: SWOG 0713
Leichman CG, McDonough SL, Smalley SR, Billingsley KG, Lenz HJ, Beldner MA, Hezel AF, Velasco MR, Guthrie KA, Blanke CD, Hochster HS. Cetuximab Combined With Induction Oxaliplatin and Capecitabine, Followed by Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: SWOG 0713. Clinical Colorectal Cancer 2017, 17: e121-e125. PMID: 29233486, PMCID: PMC6598683, DOI: 10.1016/j.clcc.2017.10.008.Peer-Reviewed Original ResearchConceptsPathologic complete responseAdvanced rectal cancerNeoadjuvant chemoradiationRectal cancerInduction chemotherapyKRAS wild-type metastatic colorectal cancerWild-type metastatic colorectal cancerThree-year disease-free survivalLocally Advanced Rectal CancerMetastatic colorectal cancerDisease-free survivalPhase III trialsAdequate hematologicEligible patientsBowel obstructionSame regimenIII trialsPerformance statusRenal functionComplete responseImproved survivalClinical outcomesMicroscopic cancerRectal adenocarcinomaPatient eligibility
2012
Loss of expression of the cancer stem cell marker aldehyde dehydrogenase 1 correlates with advanced-stage colorectal cancer
Hessman C, Bubbers E, Billingsley K, Herzig D, Wong M. Loss of expression of the cancer stem cell marker aldehyde dehydrogenase 1 correlates with advanced-stage colorectal cancer. The American Journal Of Surgery 2012, 203: 649-653. PMID: 22405917, PMCID: PMC4285581, DOI: 10.1016/j.amjsurg.2012.01.003.Peer-Reviewed Original ResearchConceptsAldehyde dehydrogenase 1Cancer stem cellsClinical outcomesLoss of expressionCSC marker aldehyde dehydrogenase 1Advanced stage colorectal cancerMarker expressionMetastatic CRC samplesAmerican Joint CommitteeLate-stage diseaseColorectal cancer progressionEffective therapeutic targetNonmetastatic CRCMetastatic diseaseEarly CRCALDH1 expressionColorectal cancerCancer stageCRC tumorsCRC samplesTumors variesDisease prognosisNonmetastatic tumorsTherapeutic targetJoint Committee
2000
Follow-up care for cancer: making the benefits equal the cost.
Schwartz D, Billingsley K, Wallner K. Follow-up care for cancer: making the benefits equal the cost. Oncology 2000, 14: 1493-8, 1501; discussion 1502-5. PMID: 11098513.Peer-Reviewed Original ResearchConceptsRecent consensus recommendationsSurvey of cliniciansInstitutional followUnproven regimensClinical outcomesClose surveillanceCommon cancerOncologic practiceConsensus recommendationsOncology organizationsFollowCancerCliniciansCareCurrent dataSignificant benefitsRegimensColorectalPatientsProstateBreastAcute need